At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
Retifanlimabdrug
Likely dose
Retifanlimab 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
In Brief
A Phase 2 clinical trial evaluating Retifanlimab for Squamous Cell Carcinoma of Anal Canal. Completed, enrolled 94 participants across 46 sites in 9 countries.
Detailed Summary
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of Anal Canal
CountriesBelgium, Denmark, France, Germany, Italy, Norway, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartOct 2018
Primary CompletionJun 2020
Study CompletionNov 2021
TodayJul 2026
First PostedJul 24, 2018
Enrollment StartOct 8, 2018
Primary CompletionJun 8, 2020
Study CompletionNov 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.9 years ago
Interventions
Retifanlimabdrug
Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).